⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TTRX News
Turn Therapeutics Inc. Common Stock
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
businesswire.com
TTRX
Form 8-K
sec.gov
TTRX
Form 8-K
sec.gov
TTRX
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
businesswire.com
TTRX
Form 8-K
sec.gov
TTRX
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
businesswire.com
TTRX
Form 8-K
sec.gov
TTRX
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
businesswire.com
TTRX
Form 8-K
sec.gov
TTRX
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
businesswire.com
TTRX